Stephen E Spurgeon

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. pmc The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia
    Stephen E Spurgeon
    Knight Cancer Institute, Oregon Health and Science University, 3181 Sam Jackson Park Road, Portland, OR 97239, USA
    J Pharmacol Exp Ther 344:378-87. 2013
  2. doi request reprint Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma
    Stephen E Spurgeon
    Knight Cancer Institute at Oregon Health and Science University, Portland, OR 97239 3098, USA
    Leuk Lymphoma 52:1488-94. 2011
  3. pmc Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma
    Matthew B Siegel
    Knight Cancer Institute, Portland, Oregon, USA
    Oncotarget 6:18921-32. 2015
  4. doi request reprint Aberrations of MYC are a common event in B-cell prolymphocytic leukemia
    Ellen Flatley
    From the Department of Pathology, Oregon Health and Science University, Portland
    Am J Clin Pathol 142:347-54. 2014
  5. pmc Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening
    Jeffrey W Tyner
    Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, OR 97239, USA
    Cancer Res 73:285-96. 2013

Collaborators

Detail Information

Publications6

  1. pmc The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia
    Stephen E Spurgeon
    Knight Cancer Institute, Oregon Health and Science University, 3181 Sam Jackson Park Road, Portland, OR 97239, USA
    J Pharmacol Exp Ther 344:378-87. 2013
    ..Our findings support the ongoing development of P505-15 as a therapeutic agent for B-cell malignancies. A dose finding study in healthy volunteers has been completed...
  2. doi request reprint Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma
    Stephen E Spurgeon
    Knight Cancer Institute at Oregon Health and Science University, Portland, OR 97239 3098, USA
    Leuk Lymphoma 52:1488-94. 2011
    ..05). There was one toxic death (neutropenic pseudomonal sepsis) related to treatment. R-cladribine is an effective therapy for previously untreated MCL, and these results validate the use of R-cladribine for the initial treatment of MCL...
  3. pmc Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma
    Matthew B Siegel
    Knight Cancer Institute, Portland, Oregon, USA
    Oncotarget 6:18921-32. 2015
    ..Our aim was to identify novel, efficacious small-molecule combinations for use in drug resistant multiple myeloma...
  4. doi request reprint Aberrations of MYC are a common event in B-cell prolymphocytic leukemia
    Ellen Flatley
    From the Department of Pathology, Oregon Health and Science University, Portland
    Am J Clin Pathol 142:347-54. 2014
    ..It is defined as a mature B-cell leukemia with more than 55% circulating prolymphocytes. Leukemic mantle cell lymphoma and chronic lymphocytic leukemia in prolymphocytic transformation must be excluded...
  5. pmc Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening
    Jeffrey W Tyner
    Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, OR 97239, USA
    Cancer Res 73:285-96. 2013
    ..Taken together, our results suggested that drug target scores derived from a comprehensive kinase inhibitor panel could predict pathway dependence in cancer cells while simultaneously identifying potential therapeutic options...